全文获取类型
收费全文 | 1710151篇 |
免费 | 121311篇 |
国内免费 | 3412篇 |
专业分类
耳鼻咽喉 | 24302篇 |
儿科学 | 49920篇 |
妇产科学 | 46490篇 |
基础医学 | 242423篇 |
口腔科学 | 50006篇 |
临床医学 | 145703篇 |
内科学 | 339809篇 |
皮肤病学 | 35978篇 |
神经病学 | 134170篇 |
特种医学 | 68157篇 |
外国民族医学 | 411篇 |
外科学 | 274482篇 |
综合类 | 34718篇 |
现状与发展 | 1篇 |
一般理论 | 471篇 |
预防医学 | 119168篇 |
眼科学 | 39197篇 |
药学 | 127419篇 |
3篇 | |
中国医学 | 3668篇 |
肿瘤学 | 98378篇 |
出版年
2018年 | 16639篇 |
2017年 | 13115篇 |
2016年 | 14259篇 |
2015年 | 16227篇 |
2014年 | 22608篇 |
2013年 | 34221篇 |
2012年 | 46218篇 |
2011年 | 48750篇 |
2010年 | 29272篇 |
2009年 | 28038篇 |
2008年 | 47401篇 |
2007年 | 49822篇 |
2006年 | 50749篇 |
2005年 | 49382篇 |
2004年 | 47536篇 |
2003年 | 45848篇 |
2002年 | 45089篇 |
2001年 | 88338篇 |
2000年 | 91201篇 |
1999年 | 76798篇 |
1998年 | 19402篇 |
1997年 | 17439篇 |
1996年 | 17391篇 |
1995年 | 16205篇 |
1994年 | 15314篇 |
1993年 | 14197篇 |
1992年 | 59111篇 |
1991年 | 56637篇 |
1990年 | 55030篇 |
1989年 | 53387篇 |
1988年 | 48969篇 |
1987年 | 48093篇 |
1986年 | 45350篇 |
1985年 | 43300篇 |
1984年 | 31534篇 |
1983年 | 26780篇 |
1982年 | 14932篇 |
1981年 | 13053篇 |
1979年 | 28595篇 |
1978年 | 19623篇 |
1977年 | 16721篇 |
1976年 | 15121篇 |
1975年 | 16668篇 |
1974年 | 20113篇 |
1973年 | 19037篇 |
1972年 | 18120篇 |
1971年 | 16907篇 |
1970年 | 16268篇 |
1969年 | 15250篇 |
1968年 | 14188篇 |
排序方式: 共有10000条查询结果,搜索用时 312 毫秒
61.
62.
E. Niclas Jonsson Rujia Xie Scott F. Marshall Rosalin H. Arends 《British journal of clinical pharmacology》2016,81(4):688-699
AimsThe aims were to 1) develop the pharmacokinetics model to describe and predict observed tanezumab concentrations over time, 2) test possible covariate parameter relationships that could influence clearance and distribution and 3) assess the impact of fixed dosing vs. a dosing regimen adjusted by body weight.MethodsIndividual concentration–time data were determined from 1608 patients in four phase 3 studies conducted to assess efficacy and safety of intravenous tanezumab. Patients received two or three intravenous doses (2.5, 5 or 10 mg) every 8 weeks. Blood samples for assessment of tanezumab PK were collected at baseline, 1 h post‐dose and at weeks 4, 8, 16 and 24 (or early termination) in all studies. Blood samples were collected at week 32 in two studies. Plasma samples were analyzed using a sensitive, specific, validated enzyme‐linked immunosorbent assay.ResultsA two compartment model with parallel linear and non‐linear elimination processes adequately described the data. Population estimates for clearance (CL), central volume (V
1), peripheral volume (V
2), inter‐compartmental clearance, maximum elimination capacity (VM) and concentration at half‐maximum elimination capacity were 0.135 l day–1, 2.71 l, 1.98 l, 0.371 l day–1, 8.03 μg day–1 and 27.7 ng ml–1, respectively. Inter‐individual variability (IIV) was included on CL, V
1, V
2 and VM. A mixture model accounted for the distribution of residual error. While gender, dose and creatinine clearance were significant covariates, only body weight as a covariate of CL, V
1 and V
2 significantly reduced IIV.ConclusionsThe small increase in variability associated with fixed dosing is consistent with other monoclonal antibodies and does not change risk : benefit. 相似文献
63.
64.
Katja T. Turunen Vasiliki Pletsa Panagiotis Georgiadis John K. Triantafillidis Dimitrios Karamanolis 《Nutrition and cancer》2016,68(4):560-567
The aim of the study was to determine the effect of β-glucan on the cytotoxicity and genotoxicity of polypectomized patient's fecal water (FW). Polypectomized volunteers (n = 69) were randomly assigned to consume bread with or without β-glucan, for 3 months. FW was collected at the beginning (t = 0), the 30th and 90th day and 2 wk after the intervention. Cytotoxicity and genotoxicity were estimated on Caco-2 cells, using trypan blue exclusion test and comet assay, respectively. Gastrointestinal symptoms were recorded and subjects kept a 3-day food diary at baseline and after completion. Trypan blue exclusion test revealed cell survival of approximately 87% after incubation with FW. The FW samples showed 49% genotoxicity at the baseline. Genotoxicity in the intervention group decreased during the trial reaching statistical significance on the 90th day compared to control. An increase was noticed 2 wk after the trial, but it still remained significantly lower compared to control. Group-specific analysis for β-glucan also revealed significant decrease in the genotoxicity on the 90th day compared to baseline. β-glucan ingestion in polypectomized patients significantly decreased the genotoxicity of their FW. Our findings suggest that β-glucan consumption could possibly provide protection against colon cancer development. 相似文献
65.
66.
Annals of Nuclear Medicine - The Response Evaluation Criteria In Solid Tumors (RECIST) is the most used radiological method for evaluating response after peptide receptor radionuclide therapy... 相似文献
67.
68.
R. Di Raimondo J. Sanz-Esporrn R. Pl I. Sanz-Martn F. Luengo F. Vignoletti J. Nuez Mariano Sanz 《Clinical oral investigations》2020,24(7):2351-2361
To evaluate the changes in alveolar contour after guided bone regeneration (GBR) with two different combinations of biomaterials in dehiscence defects arou 相似文献
69.